Images
Participants
Contact
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.
Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella are among the authors of the paper, whose first authors are from the Instituto de Biotecnología y Biomedicina of the UAB. The collaboration has also involved researchers from the universities of Barcelona, Vic and Zaragoza, the University Medical Center of Göttingen (Germany), the Sorbonne University (France), the Max Planck Institute for Experimental Medicine (Germany), and Newcastle University (UK).
Link to Público: Researchers identify a molecule that halts and reverses neurodegeneration in Parkinson’s disease (Spanish)
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
